Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidan Paishi Tablet is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of cholelithiasis (gallstones) and cholecystitis. It is manufactured by Shanghai Pharmaceuticals Group Qingdao Growful Pharmaceutical. The formulation is designed to clear heat, resolve dampness, and promote the expulsion of stones from the biliary system. It typically contains a complex mixture of botanical extracts, including *Desmodium styracifolium* (Jin Qian Cao), *Artemisia capillaris* (Yin Chen), and *Rheum palmatum* (Da Huang). These components work synergistically to increase bile production, alleviate spasms in the bile duct, and exert anti-inflammatory and antibacterial effects. It is marketed as an over-the-counter (OTC) product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidan paishi tablet.